|Calculated MW||35399 Da|
|Other Names||Apolipoprotein F, Apo-F, Lipid transfer inhibitor protein, LTIP, APOF|
|Target/Specificity||A synthetic peptide corresponding to residues in human Apolipoprotein F (apo F) was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Apolipoprotein-F (ApoF) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Minor apolipoprotein that associates with LDL. Inhibits cholesteryl ester transfer protein (CETP) activity and appears to be an important regulator of cholesterol transport. Also associates to a lesser degree with VLDL, Apo-AI and Apo-AII.|
|Tissue Location||Expressed by the liver and secreted in plasma.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Apolipoprotein F (Apo F), also known as lipid transfer inhibitor protein (LTIP) based on its ability to inhibit lipid transfer between lipoproteins, is a protein component of several lipoprotein classes and a physiologic regulator of cholesteryl ester transfer protein (CETP) function (1, 2). Apo F activity was reported to be localized to LDL, consistent with its greater inhibitory activity on this lipoprotein. Apo F activity is controlled by its reversible incorporation into an inactive complex which provides for short-term fine-tuning of lipoprotein remodeling mediated by CETP (1). ApoF overexpression reduces HDL cholesterol levels by increasing clearance of HDL-CE. ApoF may be an important determinant of HDL metabolism and reverse cholesterol transport (2).
1. He Y, et al. J Lipid Res. 49(7):1529-37, 2008
2. Lagor WR, et al. Arterioscler Thromb Vasc Biol. 29(1):40-6, 2008
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.